文献速递心外重症与机械循环支持

多学科管理策略改善连续流左心室辅助装置患者生存

Continuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach.
PubMed 文献 · Ann Thorac Surg · 2019-03-07

该单中心回顾性研究比较了124例连续流左心室辅助装置(HeartMate II)植入患者在多学科连续支持心脏团队(HTMCS)策略实施前后的结局。结果显示,HTMCS组1年生存率显著高于实施前组(100% vs 74.6%,P=0.0002),无严重不良事件生存率也有改善趋势(84.9% vs 70.4%,P=0.059)。

要点

  • HTMCS策略包括每日联合查房、药师主导抗凝、出院前转速优化超声等7项措施。
  • HTMCS组1年生存率100%,显著优于实施前组的74.6%(P=0.0002)。
  • 致残性卒中事件率在HTMCS组更低(0 vs 0.15次/患者年,P=0.019)。

核心结论

  • 实施综合多学科管理策略可显著改善连续流左心室辅助装置植入患者的结局。

研究设计与样本

  • 单中心回顾性研究,纳入2012年1月至2016年12月共124例连续接受初次HeartMate II植入的患者,所有患者完成1年随访。

主要发现

  • HTMCS组(n=53)1年生存率为100%,实施前组(n=71)为74.6%,差异有统计学意义(P=0.0002)。
  • 无严重不良事件(再次手术更换装置或致残性卒中)1年生存率HTMCS组为84.9%,实施前组为70.4%(P=0.059)。
  • 致残性卒中事件率HTMCS组为0,实施前组为0.15次/患者年(P=0.019)。
  • 消化道出血事件率HTMCS组为0.51次/患者年,实施前组为0.87次/患者年(P=0.11)。
  • 驱动线感染事件率HTMCS组为0.10次/患者年,实施前组为0.24次/患者年(P=0.18)。

关键数值与推荐

  • HTMCS策略包含7项措施:每日心脏内科/心外科/重症/药学/协调员联合查房、药师主导抗凝、出院前转速优化超声、全面泵血栓筛查与早期干预、血压门诊按搏动性调整目标、出院后早期随访及个体化长期协调员/心脏科医生分配、院内辅助人员系统培训与认证。
  • 两组基线特征(年龄、男性比例、INTERMACS 3级比例)差异无统计学意义。

临床怎么用

  • 对于植入连续流左心室辅助装置的患者,可考虑采用多学科团队策略以改善生存和减少致残性卒中。
  • 多学科策略应涵盖联合查房、抗凝管理、转速优化、血栓筛查、血压控制及系统培训等综合措施。

局限性

  • 本研究为单中心回顾性设计,样本量有限(共124例),可能存在残余混杂。
  • 原文未报告多变量校正分析或长期随访结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Continuous-flow left ventricular assist devices have revolutionized the management of advanced heart failure. Device complications continue to limit survival, but enhanced management strategies have shown promise. This study compared outcomes for HeartMate II recipients before and after implementation of a multidisciplinary continuous support heart team (HTMCS) strategy. METHODS: Between January 2012 and December 2016, 124 consecutive patients underwent primary HeartMate II implantation at our institution. In January 2015, we instituted a HTMCS approach consisting of (1) daily simultaneous cardiology/cardiac surgery/critical care/pharmacy/coordinator rounds, (2) pharmacist-directed anticoagulation, (3) speed optimization echocardiogram before discharge, (4) comprehensive device thrombosis screening and early intervention, (5) blood pressure clinic with pulsatility-adjusted goals, (6) early follow-up after discharge and individual long-term coordinator/cardiologist assignment, and (7) systematic basic/advanced/expert training and credentialing of ancillary in-hospital providers. All patients completed 1-year of follow-up. RESULTS: Demographic characteristics for pre-HTMCS (n = 71) and HTMCS (n = 53) groups, including age (55.8 ± 12.1 versus 52.5 ± 14.1 years, p = not significant), percentage of men (77.5% versus 71.7%, p = not significant), and Interagency Registry for Mechanically Assisted Circulatory Support class 3 (84.5% versus 83.0%, p = not significant), were comparable. One-year survival was 74.6% versus 100% for the pre-HTMCS and HTMCS groups, respectively (p = 0.0002). One-year survival free of serious adverse events (reoperation to replace device or disabling stroke) was 70.4% versus 84.9% for the pre-HTMCS and HTMCS groups, respectively (p = 0.059). Event per patient-year rates for disabling stroke (0.15 versus 0, p = 0.019), gastrointestinal bleeding (0.87 versus 0.51, p = 0.11), and driveline infection (0.24 versus 0.10, p = 0.18) were lower for the HTMCS group, whereas pump thrombosis requiring device exchange was higher (0.09 versus 0.18, p = 0.14). CONCLUSIONS: Implementing a comprehensive multidisciplinary approach substantially improved outcomes for recipients of continuous-flow left ventricular assist devices.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Jorde UP, Shah AM, Sims DB, et al. Continuous-Flow Left Ventricular Assist Device Survival Improves With Multidisciplinary Approach. Ann Thorac Surg. 2019. PMID: 30853587. doi:10.1016/j.athoracsur.2019.01.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。